ArticleFuture oncology (London, England)2024

Cost-effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer.

Huahua Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.